Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript
Source: SeekingAlpha
2025-11-11 04:04:03 ET
Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC November 10, 2025 4:30 PM EST...
Read the full article on Seeking Alpha
For further details see:
Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript
Xilio Therapeutics Inc.
NASDAQ: XLO
XLO Trading
-3.99% G/L:
$0.5419 Last:
205,486 Volume:
$0.545 Open:
XLO Latest News
March 02, 2026 08:00:00 am
Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference
January 08, 2026 08:30:00 am
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates
XLO Stock Data
$36,573,414
29,954,402
2.14%
13
N/A
Biotechnology & Life Sciences
Healthcare
US
Waltham
